BioMarin Pharmaceutical Inc. (BMRN) Stock Competitors & Peer Comparison
See (BMRN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BMRN | $55.90 | +2.21% | 10.8B | 40.22 | $1.39 | N/A |
| VRTX | $466.79 | +3.36% | 118.5B | 27.70 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $612.50 | +0.42% | 63.1B | 14.96 | $40.94 | +0.60% |
| ARGX | $903.75 | +2.97% | 55.9B | 40.22 | $22.47 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $286.41 | +2.99% | 38.2B | 71.96 | $3.98 | N/A |
| RVMDW | $7.12 | +3.19% | 35.8B | N/A | N/A | N/A |
| RVMD | $165.81 | +1.73% | 35.3B | -23.32 | -$7.11 | N/A |
| MRNA | $59.35 | -7.21% | 23.5B | -7.29 | -$8.14 | N/A |
Stock Comparison
BMRN vs VRTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, VRTX has a market cap of 118.5B. Regarding current trading prices, BMRN is priced at $55.90, while VRTX trades at $466.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas VRTX's P/E ratio is 27.70. In terms of profitability, BMRN's ROE is +0.04%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, BMRN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check VRTX's competition here
BMRN vs VRNA Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BMRN is priced at $55.90, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BMRN's ROE is +0.04%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, BMRN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check VRNA's competition here
BMRN vs REGN Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, REGN has a market cap of 63.1B. Regarding current trading prices, BMRN is priced at $55.90, while REGN trades at $612.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas REGN's P/E ratio is 14.96. In terms of profitability, BMRN's ROE is +0.04%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BMRN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check REGN's competition here
BMRN vs ARGX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ARGX has a market cap of 55.9B. Regarding current trading prices, BMRN is priced at $55.90, while ARGX trades at $903.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ARGX's P/E ratio is 40.22. In terms of profitability, BMRN's ROE is +0.04%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, BMRN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check ARGX's competition here
BMRN vs SGEN Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BMRN is priced at $55.90, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BMRN's ROE is +0.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BMRN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check SGEN's competition here
BMRN vs ALNY Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ALNY has a market cap of 38.2B. Regarding current trading prices, BMRN is priced at $55.90, while ALNY trades at $286.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ALNY's P/E ratio is 71.96. In terms of profitability, BMRN's ROE is +0.04%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, BMRN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ALNY's competition here
BMRN vs RVMDW Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RVMDW has a market cap of 35.8B. Regarding current trading prices, BMRN is priced at $55.90, while RVMDW trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RVMDW's P/E ratio is N/A. In terms of profitability, BMRN's ROE is +0.04%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, BMRN is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check RVMDW's competition here
BMRN vs RVMD Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RVMD has a market cap of 35.3B. Regarding current trading prices, BMRN is priced at $55.90, while RVMD trades at $165.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RVMD's P/E ratio is -23.32. In terms of profitability, BMRN's ROE is +0.04%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, BMRN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check RVMD's competition here
BMRN vs MRNA Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MRNA has a market cap of 23.5B. Regarding current trading prices, BMRN is priced at $55.90, while MRNA trades at $59.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MRNA's P/E ratio is -7.29. In terms of profitability, BMRN's ROE is +0.04%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, BMRN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check MRNA's competition here
BMRN vs RPRX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RPRX has a market cap of 23B. Regarding current trading prices, BMRN is priced at $55.90, while RPRX trades at $53.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RPRX's P/E ratio is 28.19. In terms of profitability, BMRN's ROE is +0.04%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, BMRN is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check RPRX's competition here
BMRN vs UTHR Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, BMRN is priced at $55.90, while UTHR trades at $538.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas UTHR's P/E ratio is 19.91. In terms of profitability, BMRN's ROE is +0.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BMRN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check UTHR's competition here
BMRN vs BNTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, BNTX has a market cap of 22.8B. Regarding current trading prices, BMRN is priced at $55.90, while BNTX trades at $90.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas BNTX's P/E ratio is -15.31. In terms of profitability, BMRN's ROE is +0.04%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, BMRN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check BNTX's competition here
BMRN vs ROIV Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ROIV has a market cap of 22.5B. Regarding current trading prices, BMRN is priced at $55.90, while ROIV trades at $31.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ROIV's P/E ratio is -57.87. In terms of profitability, BMRN's ROE is +0.04%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, BMRN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ROIV's competition here
BMRN vs INSM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, INSM has a market cap of 20.8B. Regarding current trading prices, BMRN is priced at $55.90, while INSM trades at $98.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas INSM's P/E ratio is -16.63. In terms of profitability, BMRN's ROE is +0.04%, compared to INSM's ROE of -1.30%. Regarding short-term risk, BMRN is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check INSM's competition here
BMRN vs BGNE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BMRN is priced at $55.90, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BMRN's ROE is +0.04%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, BMRN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check BGNE's competition here
BMRN vs INCY Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, BMRN is priced at $55.90, while INCY trades at $103.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas INCY's P/E ratio is 13.87. In terms of profitability, BMRN's ROE is +0.04%, compared to INCY's ROE of +0.29%. Regarding short-term risk, BMRN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check INCY's competition here
BMRN vs DNA-WT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BMRN is priced at $55.90, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BMRN's ROE is +0.04%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, BMRN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check DNA-WT's competition here
BMRN vs NBIX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, NBIX has a market cap of 16.3B. Regarding current trading prices, BMRN is priced at $55.90, while NBIX trades at $161.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas NBIX's P/E ratio is 24.83. In terms of profitability, BMRN's ROE is +0.04%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, BMRN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check NBIX's competition here
BMRN vs GMAB Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, GMAB has a market cap of 15.7B. Regarding current trading prices, BMRN is priced at $55.90, while GMAB trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas GMAB's P/E ratio is 19.55. In terms of profitability, BMRN's ROE is +0.04%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, BMRN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check GMAB's competition here
BMRN vs ASND Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, BMRN is priced at $55.90, while ASND trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ASND's P/E ratio is 25.97. In terms of profitability, BMRN's ROE is +0.04%, compared to ASND's ROE of -56.42%. Regarding short-term risk, BMRN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ASND's competition here
BMRN vs JAZZ Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, JAZZ has a market cap of 14.1B. Regarding current trading prices, BMRN is priced at $55.90, while JAZZ trades at $225.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas JAZZ's P/E ratio is 2042.36. In terms of profitability, BMRN's ROE is +0.04%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, BMRN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check JAZZ's competition here
BMRN vs BBIO Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, BMRN is priced at $55.90, while BBIO trades at $68.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas BBIO's P/E ratio is -18.42. In terms of profitability, BMRN's ROE is +0.04%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, BMRN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check BBIO's competition here
BMRN vs EXEL Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, BMRN is priced at $55.90, while EXEL trades at $51.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas EXEL's P/E ratio is 17.00. In terms of profitability, BMRN's ROE is +0.04%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, BMRN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check EXEL's competition here
BMRN vs AXSM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, AXSM has a market cap of 12.8B. Regarding current trading prices, BMRN is priced at $55.90, while AXSM trades at $247.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas AXSM's P/E ratio is -66.45. In terms of profitability, BMRN's ROE is +0.04%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, BMRN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check AXSM's competition here
BMRN vs KRTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BMRN is priced at $55.90, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BMRN's ROE is +0.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BMRN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check KRTX's competition here
BMRN vs IONS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, BMRN is priced at $55.90, while IONS trades at $75.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas IONS's P/E ratio is -36.88. In terms of profitability, BMRN's ROE is +0.04%, compared to IONS's ROE of -0.59%. Regarding short-term risk, BMRN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check IONS's competition here
BMRN vs MDGL Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, BMRN is priced at $55.90, while MDGL trades at $512.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MDGL's P/E ratio is -37.99. In terms of profitability, BMRN's ROE is +0.04%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, BMRN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check MDGL's competition here
BMRN vs ARWR Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ARWR has a market cap of 11.6B. Regarding current trading prices, BMRN is priced at $55.90, while ARWR trades at $82.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ARWR's P/E ratio is -36.12. In terms of profitability, BMRN's ROE is +0.04%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, BMRN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ARWR's competition here
BMRN vs RNAM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BMRN is priced at $55.90, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BMRN's ROE is +0.04%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BMRN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check RNAM's competition here
BMRN vs SMMT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, BMRN is priced at $55.90, while SMMT trades at $14.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas SMMT's P/E ratio is -8.98. In terms of profitability, BMRN's ROE is +0.04%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, BMRN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check SMMT's competition here
BMRN vs KRYS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, BMRN is priced at $55.90, while KRYS trades at $343.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas KRYS's P/E ratio is 45.91. In terms of profitability, BMRN's ROE is +0.04%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BMRN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check KRYS's competition here
BMRN vs CYTK Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CYTK has a market cap of 9.9B. Regarding current trading prices, BMRN is priced at $55.90, while CYTK trades at $79.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CYTK's P/E ratio is -11.54. In terms of profitability, BMRN's ROE is +0.04%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, BMRN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CYTK's competition here
BMRN vs RXDX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BMRN is priced at $55.90, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BMRN's ROE is +0.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BMRN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check RXDX's competition here
BMRN vs NUVL Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, BMRN is priced at $55.90, while NUVL trades at $123.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas NUVL's P/E ratio is -20.37. In terms of profitability, BMRN's ROE is +0.04%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BMRN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check NUVL's competition here
BMRN vs IMGN Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BMRN is priced at $55.90, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BMRN's ROE is +0.04%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BMRN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check IMGN's competition here
BMRN vs TECH Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, TECH has a market cap of 8.7B. Regarding current trading prices, BMRN is priced at $55.90, while TECH trades at $55.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas TECH's P/E ratio is 79.44. In terms of profitability, BMRN's ROE is +0.04%, compared to TECH's ROE of +0.05%. Regarding short-term risk, BMRN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check TECH's competition here
BMRN vs CORT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CORT has a market cap of 8.6B. Regarding current trading prices, BMRN is priced at $55.90, while CORT trades at $79.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CORT's P/E ratio is 227.74. In terms of profitability, BMRN's ROE is +0.04%, compared to CORT's ROE of +0.08%. Regarding short-term risk, BMRN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CORT's competition here
BMRN vs BPMC Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BMRN is priced at $55.90, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BMRN's ROE is +0.04%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, BMRN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check BPMC's competition here
BMRN vs TGTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, BMRN is priced at $55.90, while TGTX trades at $54.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas TGTX's P/E ratio is 19.02. In terms of profitability, BMRN's ROE is +0.04%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, BMRN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check TGTX's competition here
BMRN vs APGE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, BMRN is priced at $55.90, while APGE trades at $132.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas APGE's P/E ratio is -30.61. In terms of profitability, BMRN's ROE is +0.04%, compared to APGE's ROE of -0.33%. Regarding short-term risk, BMRN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check APGE's competition here
BMRN vs CERE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BMRN is priced at $55.90, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CERE's P/E ratio is -16.47. In terms of profitability, BMRN's ROE is +0.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BMRN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check CERE's competition here
BMRN vs HALO Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, BMRN is priced at $55.90, while HALO trades at $68.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas HALO's P/E ratio is 24.21. In terms of profitability, BMRN's ROE is +0.04%, compared to HALO's ROE of +1.26%. Regarding short-term risk, BMRN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check HALO's competition here
BMRN vs KYMR Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, KYMR has a market cap of 8.2B. Regarding current trading prices, BMRN is priced at $55.90, while KYMR trades at $99.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas KYMR's P/E ratio is -27.78. In terms of profitability, BMRN's ROE is +0.04%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, BMRN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check KYMR's competition here
BMRN vs ALKS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, BMRN is priced at $55.90, while ALKS trades at $46.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ALKS's P/E ratio is 51.13. In terms of profitability, BMRN's ROE is +0.04%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, BMRN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ALKS's competition here
BMRN vs IBRX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, BMRN is priced at $55.90, while IBRX trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas IBRX's P/E ratio is -8.49. In terms of profitability, BMRN's ROE is +0.04%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, BMRN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check IBRX's competition here
BMRN vs PCVX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, PCVX has a market cap of 7.5B. Regarding current trading prices, BMRN is priced at $55.90, while PCVX trades at $52.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas PCVX's P/E ratio is -7.56. In terms of profitability, BMRN's ROE is +0.04%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, BMRN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check PCVX's competition here
BMRN vs MTSR Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BMRN is priced at $55.90, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BMRN's ROE is +0.04%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, BMRN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check MTSR's competition here
BMRN vs PTGX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, PTGX has a market cap of 7.4B. Regarding current trading prices, BMRN is priced at $55.90, while PTGX trades at $115.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas PTGX's P/E ratio is -63.55. In terms of profitability, BMRN's ROE is +0.04%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, BMRN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check PTGX's competition here
BMRN vs IMVT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, IMVT has a market cap of 7.3B. Regarding current trading prices, BMRN is priced at $55.90, while IMVT trades at $38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas IMVT's P/E ratio is -12.76. In terms of profitability, BMRN's ROE is +0.04%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, BMRN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check IMVT's competition here
BMRN vs RYTM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, BMRN is priced at $55.90, while RYTM trades at $101.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RYTM's P/E ratio is -32.39. In terms of profitability, BMRN's ROE is +0.04%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, BMRN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check RYTM's competition here
BMRN vs MRUS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BMRN is priced at $55.90, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BMRN's ROE is +0.04%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, BMRN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check MRUS's competition here
BMRN vs ACLX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BMRN is priced at $55.90, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BMRN's ROE is +0.04%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BMRN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check ACLX's competition here
BMRN vs PTCT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, PTCT has a market cap of 6.7B. Regarding current trading prices, BMRN is priced at $55.90, while PTCT trades at $80.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas PTCT's P/E ratio is -31.87. In terms of profitability, BMRN's ROE is +0.04%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, BMRN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check PTCT's competition here
BMRN vs LQDA Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, LQDA has a market cap of 6.7B. Regarding current trading prices, BMRN is priced at $55.90, while LQDA trades at $75.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas LQDA's P/E ratio is 444.06. In terms of profitability, BMRN's ROE is +0.04%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, BMRN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check LQDA's competition here
BMRN vs ABVX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, BMRN is priced at $55.90, while ABVX trades at $101.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ABVX's P/E ratio is -19.00. In terms of profitability, BMRN's ROE is +0.04%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, BMRN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ABVX's competition here
BMRN vs RETA Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BMRN is priced at $55.90, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RETA's P/E ratio is -66.29. In terms of profitability, BMRN's ROE is +0.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BMRN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check RETA's competition here
BMRN vs PRAX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, BMRN is priced at $55.90, while PRAX trades at $303.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas PRAX's P/E ratio is -22.60. In terms of profitability, BMRN's ROE is +0.04%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, BMRN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check PRAX's competition here
BMRN vs CNTA Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, BMRN is priced at $55.90, while CNTA trades at $40.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CNTA's P/E ratio is -22.57. In terms of profitability, BMRN's ROE is +0.04%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BMRN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check CNTA's competition here
BMRN vs COGT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, COGT has a market cap of 6.1B. Regarding current trading prices, BMRN is priced at $55.90, while COGT trades at $35.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas COGT's P/E ratio is -16.52. In terms of profitability, BMRN's ROE is +0.04%, compared to COGT's ROE of -0.83%. Regarding short-term risk, BMRN is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check COGT's competition here
BMRN vs SYRE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, SYRE has a market cap of 6.1B. Regarding current trading prices, BMRN is priced at $55.90, while SYRE trades at $100.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas SYRE's P/E ratio is -47.32. In terms of profitability, BMRN's ROE is +0.04%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, BMRN is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check SYRE's competition here
BMRN vs BLTE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, BMRN is priced at $55.90, while BLTE trades at $147.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas BLTE's P/E ratio is -57.90. In terms of profitability, BMRN's ROE is +0.04%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, BMRN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check BLTE's competition here
BMRN vs SRRK Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, BMRN is priced at $55.90, while SRRK trades at $49.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas SRRK's P/E ratio is -14.22. In terms of profitability, BMRN's ROE is +0.04%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, BMRN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check SRRK's competition here
BMRN vs CGON Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CGON has a market cap of 5.8B. Regarding current trading prices, BMRN is priced at $55.90, while CGON trades at $66.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CGON's P/E ratio is -28.31. In terms of profitability, BMRN's ROE is +0.04%, compared to CGON's ROE of -0.23%. Regarding short-term risk, BMRN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CGON's competition here
BMRN vs CDTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BMRN is priced at $55.90, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BMRN's ROE is +0.04%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, BMRN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check CDTX's competition here
BMRN vs ABCM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BMRN is priced at $55.90, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BMRN's ROE is +0.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BMRN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check ABCM's competition here
BMRN vs ISEE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BMRN is priced at $55.90, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BMRN's ROE is +0.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BMRN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check ISEE's competition here
BMRN vs LEGN Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, BMRN is priced at $55.90, while LEGN trades at $29.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas LEGN's P/E ratio is -21.26. In terms of profitability, BMRN's ROE is +0.04%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, BMRN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check LEGN's competition here
BMRN vs MIRM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, BMRN is priced at $55.90, while MIRM trades at $107.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MIRM's P/E ratio is -7.91. In terms of profitability, BMRN's ROE is +0.04%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, BMRN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check MIRM's competition here
BMRN vs FBIOX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, BMRN is priced at $55.90, while FBIOX trades at $26.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas FBIOX's P/E ratio is N/A. In terms of profitability, BMRN's ROE is +0.04%, compared to FBIOX's ROE of N/A. Regarding short-term risk, BMRN is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check FBIOX's competition here
BMRN vs LGND Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, LGND has a market cap of 5.3B. Regarding current trading prices, BMRN is priced at $55.90, while LGND trades at $262.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas LGND's P/E ratio is 34.05. In terms of profitability, BMRN's ROE is +0.04%, compared to LGND's ROE of +0.16%. Regarding short-term risk, BMRN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check LGND's competition here
BMRN vs APLS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BMRN is priced at $55.90, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas APLS's P/E ratio is 38.35. In terms of profitability, BMRN's ROE is +0.04%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BMRN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check APLS's competition here
BMRN vs CRSP Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, BMRN is priced at $55.90, while CRSP trades at $54.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CRSP's P/E ratio is -8.81. In terms of profitability, BMRN's ROE is +0.04%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, BMRN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CRSP's competition here
BMRN vs TVTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, TVTX has a market cap of 5.1B. Regarding current trading prices, BMRN is priced at $55.90, while TVTX trades at $55.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas TVTX's P/E ratio is -110.22. In terms of profitability, BMRN's ROE is +0.04%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, BMRN is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check TVTX's competition here
BMRN vs CAI Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, BMRN is priced at $55.90, while CAI trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CAI's P/E ratio is -6.27. In terms of profitability, BMRN's ROE is +0.04%, compared to CAI's ROE of +0.06%. Regarding short-term risk, BMRN is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CAI's competition here
BMRN vs TERN Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BMRN is priced at $55.90, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas TERN's P/E ratio is -51.41. In terms of profitability, BMRN's ROE is +0.04%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BMRN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check TERN's competition here
BMRN vs ERAS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, BMRN is priced at $55.90, while ERAS trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ERAS's P/E ratio is -16.22. In terms of profitability, BMRN's ROE is +0.04%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, BMRN is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ERAS's competition here
BMRN vs FOLD Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $55.90, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BMRN's ROE is +0.04%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BMRN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check FOLD's competition here
BMRN vs AKRO Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $55.90, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BMRN's ROE is +0.04%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, BMRN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check AKRO's competition here
BMRN vs ALPN Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $55.90, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BMRN's ROE is +0.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BMRN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check ALPN's competition here
BMRN vs CELC Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, BMRN is priced at $55.90, while CELC trades at $89.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CELC's P/E ratio is -23.06. In terms of profitability, BMRN's ROE is +0.04%, compared to CELC's ROE of -2.45%. Regarding short-term risk, BMRN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CELC's competition here
BMRN vs XENE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, BMRN is priced at $55.90, while XENE trades at $54.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas XENE's P/E ratio is -11.66. In terms of profitability, BMRN's ROE is +0.04%, compared to XENE's ROE of -0.49%. Regarding short-term risk, BMRN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check XENE's competition here
BMRN vs KNSA Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, BMRN is priced at $55.90, while KNSA trades at $57.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas KNSA's P/E ratio is 62.78. In terms of profitability, BMRN's ROE is +0.04%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, BMRN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check KNSA's competition here
BMRN vs MANE Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, BMRN is priced at $55.90, while MANE trades at $102.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MANE's P/E ratio is -38.78. In terms of profitability, BMRN's ROE is +0.04%, compared to MANE's ROE of -0.95%. Regarding short-term risk, BMRN is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check MANE's competition here
BMRN vs VCYT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, VCYT has a market cap of 4.2B. Regarding current trading prices, BMRN is priced at $55.90, while VCYT trades at $53.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas VCYT's P/E ratio is 49.25. In terms of profitability, BMRN's ROE is +0.04%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, BMRN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check VCYT's competition here
BMRN vs OPT Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BMRN is priced at $55.90, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas OPT's P/E ratio is -1.52. In terms of profitability, BMRN's ROE is +0.04%, compared to OPT's ROE of +1.09%. Regarding short-term risk, BMRN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check OPT's competition here
BMRN vs MRTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BMRN is priced at $55.90, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BMRN's ROE is +0.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BMRN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check MRTX's competition here
BMRN vs DFTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, DFTX has a market cap of 4B. Regarding current trading prices, BMRN is priced at $55.90, while DFTX trades at $36.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas DFTX's P/E ratio is N/A. In terms of profitability, BMRN's ROE is +0.04%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, BMRN is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check DFTX's competition here
BMRN vs EWTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, EWTX has a market cap of 3.9B. Regarding current trading prices, BMRN is priced at $55.90, while EWTX trades at $36.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas EWTX's P/E ratio is -21.99. In terms of profitability, BMRN's ROE is +0.04%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, BMRN is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check EWTX's competition here
BMRN vs CPRX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, BMRN is priced at $55.90, while CPRX trades at $31.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CPRX's P/E ratio is 18.14. In terms of profitability, BMRN's ROE is +0.04%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BMRN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check CPRX's competition here
BMRN vs DNLI Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, BMRN is priced at $55.90, while DNLI trades at $24.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas DNLI's P/E ratio is -8.35. In terms of profitability, BMRN's ROE is +0.04%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, BMRN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check DNLI's competition here
BMRN vs ACAD Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, BMRN is priced at $55.90, while ACAD trades at $22.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas ACAD's P/E ratio is 10.00. In terms of profitability, BMRN's ROE is +0.04%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, BMRN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check ACAD's competition here
BMRN vs VKTX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, BMRN is priced at $55.90, while VKTX trades at $32.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas VKTX's P/E ratio is -7.80. In terms of profitability, BMRN's ROE is +0.04%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, BMRN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check VKTX's competition here
BMRN vs RYZB Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BMRN is priced at $55.90, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BMRN's ROE is +0.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BMRN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check RYZB's competition here
BMRN vs CRNX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, BMRN is priced at $55.90, while CRNX trades at $35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CRNX's P/E ratio is -6.88. In terms of profitability, BMRN's ROE is +0.04%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BMRN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check CRNX's competition here
BMRN vs CBAY Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BMRN is priced at $55.90, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BMRN's ROE is +0.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BMRN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BMRN.Check CBAY's competition here
BMRN vs BEAM Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, BEAM has a market cap of 3.7B. Regarding current trading prices, BMRN is priced at $55.90, while BEAM trades at $35.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas BEAM's P/E ratio is -72.51. In terms of profitability, BMRN's ROE is +0.04%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, BMRN is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check BEAM's competition here
BMRN vs DNTH Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, BMRN is priced at $55.90, while DNTH trades at $87.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas DNTH's P/E ratio is -20.65. In terms of profitability, BMRN's ROE is +0.04%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, BMRN is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check DNTH's competition here
BMRN vs NAMS Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, BMRN is priced at $55.90, while NAMS trades at $30.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas NAMS's P/E ratio is -17.31. In terms of profitability, BMRN's ROE is +0.04%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, BMRN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check NAMS's competition here
BMRN vs TNGX Comparison June 2026
BMRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 10.8B. In comparison, TNGX has a market cap of 3.5B. Regarding current trading prices, BMRN is priced at $55.90, while TNGX trades at $28.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 40.22, whereas TNGX's P/E ratio is -34.34. In terms of profitability, BMRN's ROE is +0.04%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, BMRN is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for BMRN.Check TNGX's competition here